Core Points - The implementation rules for cumulative voting at Cyrus Medical Technology Group are established to protect the rights of minority shareholders and ensure compliance with relevant laws and regulations [1][4] - Cumulative voting will be applied when the company elects or replaces directors, particularly when a single shareholder or their concerted parties hold 30% or more of the voting shares and when electing two or more independent directors [1][2] Summary by Sections Cumulative Voting System - The cumulative voting system allows each share to have voting rights equal to the number of directors to be elected, enabling shareholders to concentrate their votes on one candidate or distribute them among several [1][2] - The voting process requires shareholders to indicate their chosen directors and the number of votes allocated to each on a single ballot [2][4] Voting Procedures - If the total votes used by a shareholder exceed their legal voting rights, the ballot will be considered invalid unless corrected [2][4] - The counting of votes will be conducted by the monitoring personnel, and the elected directors must receive more than half of the votes from the attending shareholders [2][4] Information Disclosure - The company is obligated to disclose information regarding the voting system used, the absolute number of votes received by elected directors, and any other relevant matters deemed necessary by the board or independent directors [4] Nomination and Implementation - The nomination procedures for director candidates will follow the company's articles of association [4] - The implementation rules will take effect upon approval by the company's shareholders' meeting and will be interpreted and revised by the board of directors [4]

塞力斯医疗科技集团股份有限公司 信息披露管理制度 塞力斯医疗科技集团股份有限公司 信息披露管理制度 （2025 年 8 月） 第一章 总则 第一条 为了规范塞力斯医疗科技集团股份有限公司（以下简称"公司"） 的信息披露行为，加强信息披露事务管理，保护投资者合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司信息披露管理办法》《上海证券交易所股票上市规则》等法律法规、规章、 规范性文件及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司章 程》"）的规定，制定本制度。 第二条 信息披露义务人应当及时依法履行信息披露义务，披露的信息应当 真实、准确、完整，简明清晰、通俗易懂，不得有虚假记载、误导性陈述或者重 大遗漏。 信息披露义务人披露的信息应当同时向所有投资者披露，不得提前向任何单 位和个人泄露。但是，法律、行政法规另有规定的除外。 在内幕信息依法披露前，内幕信息的知情人和非法获取内幕信息的人不得公 开或者泄露该信息，不得利用该信息进行内幕交易。任何单位和个人不得非法要 求信息披露义务人提供依法需要披露但尚未披露的信息。 公司证券及其衍生品种同时在境内境外 ...

塞力斯医疗科技集团股份有限公司 重大交易决策制度 塞力斯医疗科技集团股份有限公司 重大交易决策制度 （2025 年 8 月） 第一条 为加强对塞力斯医疗科技集团股份有限公司（以下简称"公司"） 重大交易活动的决策管理，保证重大交易活动的规范性、合法性和效益性，切 实保护公司利益各方的合法权益，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上海证券交易所股票上市规则》等相关法律、法规和《塞力 斯医疗科技集团股份有限公司章程》（以下简称"《公司章程》"）的规定， 制定本制度。 第二条 公司应当严格遵守有关法律、法规及《公司章程》的规定，在交 易决策中，保障股东会、董事会和董事长、经理（总裁）各自的权限得到有效 发挥，做到权责分明，保证公司运作效率。 第三条 本制度所称"重大交易"包括除公司日常经营活动之外发生的下 列事项： (一)购买或出售资产； (二)对外投资（含委托理财、对子公司投资等）； (三)提供财务资助（含有息或者无息借款、委托贷款等）； (四)提供担保（含对控股子公司担保等）； (十一)放弃权利（含放弃优先购买权、优先认缴出资权等）； (十二)证券交易所认定的其他交易。 塞力斯医疗科技集团股 ...

Core Viewpoint - The document outlines the information disclosure deferral and exemption management system for Celis Medical Technology Group Co., Ltd, aiming to ensure compliance with legal obligations and protect investors' rights [1][2]. Group 1: Information Disclosure Management - The company and other obligated parties must disclose information truthfully, accurately, completely, timely, and fairly, without abusing deferral or exemption to mislead investors [1][2]. - The scope of deferral and exemption should generally align with the conditions at the time of the company's initial public offering, requiring substantial evidence for any additions post-listing [2][3]. Group 2: Confidential Information - Information that involves state secrets or commercial secrets can be exempted from disclosure if it could lead to violations of confidentiality regulations or cause significant harm to the company or others [2][3]. - If the reasons for deferral or exemption are no longer valid, or if the information becomes difficult to keep confidential, timely disclosure is required [3][4]. Group 3: Internal Procedures - Relevant departments must submit documentation and confidentiality agreements three days prior to any event for which deferral or exemption is requested, which will be reviewed by the securities department [4][5]. - The company must maintain a record of all deferrals and exemptions, including the reasons for such actions and the internal review process, for a minimum of ten years [5][6]. Group 4: Accountability and Compliance - The company has established a responsibility accountability mechanism for information disclosure, with penalties for those who fail to comply with the established rules or do not disclose information in a timely manner after the reasons for deferral have been resolved [5][6]. - The system will take effect upon approval by the board of directors and will be subject to interpretation by the board [6].

Core Points - The financing management system of Cyrus Medical Technology Group aims to standardize financing activities, enhance financial monitoring, reduce financing costs, and effectively prevent financial risks while protecting the rights of shareholders [1][2]. Group 1: General Principles - The financing activities are applicable to the company and its wholly-owned and controlling subsidiaries, with reference for joint ventures [1]. - The financing referred to in this system is limited to debt financing, excluding equity financing [1]. - Financing activities should align with the company's medium to long-term strategic development plan, considering factors such as capital structure, debt repayment capability, and long-term versus short-term benefits [1]. Group 2: Internal Control Objectives - The internal control objectives for financing activities include ensuring appropriate review before financing occurs, compliance with legal regulations, accurate interest and dividend payments, and reasonable confirmation of shareholder rights [2]. Group 3: Organization and Responsibilities - The company manager is responsible for overseeing financing management, including organizing the financing management system, planning, and supervising financing activities [3]. - The finance department conducts regular and irregular audits of financing activities [3]. - The management of subsidiaries is responsible for approving financing projects within the board's authorized scope [3]. Group 4: Financing Decision Management - Borrowing from banks must comply with relevant regulations, prioritizing the company's reputation and timely repayment to avoid penalties [3][4]. - Financing matters must be approved by the manager, board of directors, and shareholders based on the amount of financing relative to the company's audited net assets [5][6]. Group 5: Financing Process Management - Key financing processes include determining funding needs, preparing financing plans, selecting financing methods, signing contracts, and managing interest and dividend payments [6]. Group 6: Financing Result Evaluation - The finance department is responsible for evaluating financing results, ensuring legal authorization, compliance with regulations, and assessing the actual benefits and future impacts of financing [6].

Core Viewpoint - The company has established a system for accountability regarding significant errors in annual report disclosures to enhance the quality and transparency of information provided to stakeholders [2][3]. Group 1: General Principles - The system aims to strengthen the company's operational standards and increase accountability for those responsible for annual report disclosures [2]. - It is based on relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2]. - The accountability system applies to directors, senior management, subsidiary heads, controlling shareholders, and other personnel involved in annual report disclosures [2][3]. Group 2: Conditions for Accountability - Specific conditions under which responsibility should be pursued include violations of national laws and regulations that lead to significant errors in annual report disclosures [3]. - There are provisions for heavier penalties in cases of severe misconduct or negligence [3]. - Conversely, there are also conditions under which penalties may be reduced or waived [3]. Group 3: Forms and Types of Accountability - The forms of accountability include disciplinary actions and potential economic penalties determined by the board based on the severity of the incident [4]. - The company ensures that before any penalties are imposed, the responsible individuals have the right to present their opinions and defend themselves [3][4]. Group 4: Supplementary Provisions - Any matters not covered by this system will refer to relevant laws, regulations, and the company's articles of association [6]. - The system will take effect upon approval by the board of directors and will be subject to interpretation and revision by the board [6].

General Principles - The purpose of the insider information management system is to regulate the management of insider information, enhance confidentiality, and maintain the principles of public, fair, and just information disclosure [2][3] - The system is established in accordance with various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2] Responsibilities - The chairman of the board is the primary responsible person for the management of insider information and must ensure the accuracy and completeness of the insider information records [2][3] - The board secretary is responsible for the daily management of insider information and must cooperate with the chairman in maintaining confidentiality [3] Definition of Insider Information - Insider information refers to non-public information that could significantly impact the company's operations, finances, or stock market prices [3][4] - Specific events that qualify as insider information include major asset restructuring, significant changes in shareholder equity, and other events that could affect stock prices [4][5] Registration and Disclosure of Insider Information - The company must report insider information to the stock exchange when significant events occur, such as major asset restructuring or changes in control [4][5] - Insider information must be documented, including details about the individuals who are privy to such information and the circumstances under which they gained access [5][6] Confidentiality Obligations - Individuals with insider information are required to maintain confidentiality and are prohibited from disclosing or trading based on that information before it is publicly disclosed [5][10] - The company must take necessary measures to limit the number of individuals who have access to insider information [5][11] Record Keeping - The company must maintain detailed records of insider information, including the names and details of individuals who have access to such information, and the circumstances of their access [6][7] - Records must be updated and submitted to regulatory bodies within specified timeframes following the public disclosure of insider information [6][8] Accountability and Penalties - Violations of the insider information management system may result in disciplinary actions, including potential legal consequences for severe breaches [13][14] - The company reserves the right to pursue accountability against individuals or entities that cause losses due to violations of the insider information regulations [13][14]

塞力斯医疗科技集团股份有限公司 投资者关系管理制度 塞力斯医疗科技集团股份有限公司 投资者关系管理制度 （2025年8月） 第一章 总则 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"）与投 资者之间的信息沟通，促进投资者对公司的了解和认同，促进公司诚信自律、规 范运作，保持诚信、公正、透明的对外形象，更好地服务于投资者，根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司投资者关系管理工作 指引》《上海证券交易所股票上市规则》（以下简称"《上市规则》"）、《上海 证券交易所上市公司自律监管指引第1号——规范运作》及其他适用法律、法规、 规范性文件以及《塞力斯医疗科技集团股份有限公司章程》（以下简称"《公司 章程》"）的规定，结合公司实际情况，制定本制度。 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 公司控股股东、实际控制人以及董事和高级管理人员应当高度重视、 积极参与和 ...

塞力斯医疗科技集团股份有限公司 内部控制制度 塞力斯医疗科技集团股份有限公司 内部控制制度 （2025年8月） 第一章 总则 第一条 为加强塞力斯医疗科技集团股份有限公司（以下简称"公司"）内 部控制，促进公司规范运作和健康发展，保护投资者合法权益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上海证券交易所股票上市规则》 等法律法规的规定，结合公司的实际情况，制定本制度。 第二条 公司内部控制制度的目的： （一）遵守国家法律、法规、规章及其他相关规定； （二）提高公司经营的效益及效率，提升公司质量，增加对公司股东的回 报； （三）保障公司资产的安全、完整； （四）确保公司信息披露的真实、准确、完整和公平。 第三条 公司董事会应对公司内部控制制度的制定和有效执行负责。 第二章 内部控制的内容 第四条 公司的内部控制主要包括：环境控制、业务控制、会计系统控制、 信息传递控制、内部审计控制等内容。 第五条 公司应不断完善公司治理结构，确保董事会和股东会等机构合法运 作和科学决策，公司将逐步建立有效的激励约束机制，树立风险防范意识，培 育良好的企业精神和内部控制文化，创造全体职工充分了解并履行职责的环境。 ...

Core Viewpoint - The internal audit system of Selis Medical Technology Group Co., Ltd. aims to standardize internal audit work, clarify the responsibilities of internal audit institutions and personnel, and enhance internal control, operational management, and economic efficiency [1]. Group 1: Internal Audit Definition and Structure - Internal audit refers to the evaluation activities conducted by the company's internal audit institution or personnel to assess the effectiveness of internal control and risk management, the authenticity and completeness of financial information, and the efficiency and effectiveness of operational activities [1]. - The internal audit department must maintain independence and should not be under the leadership of the finance department or share office space with it [1][2]. Group 2: Responsibilities and Duties of Internal Audit - The internal audit institution is responsible for checking and evaluating the completeness, rationality, and effectiveness of internal control systems across the company and its subsidiaries [12]. - It must audit the legality, compliance, authenticity, and completeness of accounting and economic data, including financial reports and performance forecasts [12]. - The internal audit department should report to the audit committee at least quarterly, covering the execution of the internal audit plan and issues discovered during the audit [12]. Group 3: Audit Procedures and Reporting - The internal audit institution must submit the next year's internal audit work plan to the audit committee two months before the end of each accounting year and an annual audit report two months after the year-end [13]. - The internal audit process includes planning, execution, and reporting, with a focus on obtaining sufficient, relevant, and reliable audit evidence to support conclusions and recommendations [34][12]. Group 4: Internal Control Evaluation - Internal audit should evaluate the effectiveness of internal controls related to financial reporting and information disclosure, including the establishment and implementation of internal control systems [18]. - The internal audit institution must supervise the implementation of corrective measures for any identified internal control deficiencies [19]. Group 5: Rights and Powers of Internal Audit - The internal audit institution has the authority to formulate internal audit regulations, participate in financial management meetings, and request relevant documents from the audited entities [28][29]. - It can also take necessary measures against individuals obstructing the audit process and report significant issues promptly [30][31]. Group 6: Confidentiality and Ethics - Internal audit personnel must adhere to professional ethics, maintain confidentiality regarding audit matters, and avoid conflicts of interest [8][9]. - Any discovered serious violations or fraudulent activities must be reported to the relevant authorities for corrective action [37].